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Olive-Oil-Derived Polyphenols Effectively Attenuate
Inflammatory Responses of Human Keratinocytes by
Interfering with the NF-𝜿B Pathway
Marina Aparicio-Soto, Davender Redhu, Marina Sánchez-Hidalgo,
José G. Fernández-Bolaños, Catalina Alarcón-de-la-Lastra, Margitta Worm,
and Magda Babina*
Scope: Extra virgin olive oil (EVOO) is rich in phenolic compounds, including
hydroxytyrosol (HTy) and hydroxytyrosyl acetate (HTy-Ac), which have
presented multiple beneficial properties. Their impact on inflammatory
responses in human keratinocytes and modes of action have not been
addressed yet.
Methods and results: Primary human keratinocytes are pretreated with
HTy-Ac or HTy for 30 min and stimulated with IL-1𝜷 or Toll-like receptor 3
ligand (TLR3-l). Thymic stromal lymphopoietin (TSLP), measured by ELISA, is
attenuated by both polyphenols in a dose-dependent manner. The expression
of several inflammation-related genes, including distinct TSLP isoforms and
IL-8, are assessed by quantitative RT-PCR and likewise inhibited by
HTy-Ac/HTy. Mechanistically, EVOO phenols counteracts I𝜿B degradation
and translocation of NF-𝜿B to the nucleus, a transcription factor of essential
significance to TSLP and IL-8 transcriptional activity; this is evidenced by
immunoblotting. Accordingly, NF-𝜿B recruitment to critical binding sites in
the TSLP and IL-8 promoter is impeded in the presence of HTy-Ac/HTy, as
demonstrated by chromatin immunoprecipitation. Promoter reporter assays
finally reveal that the neutralizing effect on NF-𝜿B induction has functional
consequences, resulting in reduced NF-𝜿B-directed transcription.
Conclusion: EVOO phenols afford protection from inflammation in human
keratinocytes by interference with the NF-𝜿B pathway.
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1. Introduction
The skin is the largest organ and rep-
resent the first line defense against
external irritants and pathogens of
an organism. It is composed of the
dermis and epidermis, with the latter
forming the outer avascular segment
that consists mostly of keratinocytes
(>90%). Keratinocytes act as sentinels
organizing immune responses during
infection by production of cytokines
like IL-1, IL-6, IL-8, and tumor necrosis
factor (TNF).[1–3] When aberrantly regu-
lated or not properly counter-balanced,
keratinocyte-derived mediators can
contribute to auto-inflammatory pro-
cesses and a spectrum of skin diseases.
Thymic stromal lymphopoietin
(TSLP), an influential keratinocyte-
derived mediator, is triggered by physi-
cal, chemical, or biological disturbance
of skin homeostasis.[4–6] It is directly
associated with inflammatory and hyper-
sensitivity responses occurring at barrier
surfaces, as well as with Th2 immunity
and chronic dermatoses like atopic der-
matitis (AD) and psoriasis.[7–9] TSLP is
expressed in two isoforms with different
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immunomodulatory roles: a short isoform, expressed in skin
mainly under homeostatic conditions and a long isoform,
which is exclusively expressed under inflammatory or otherwise
pathogenic circumstances.[10,11] The two isoforms are controlled
by different promoter usage.[12,13]
Extra virgin olive oil (EVOO), the major source of fatty
acids in the traditional Mediterranean diet, is rich in phe-
nolic compounds, such as secoiridoid derivatives of 2-(3,4-
dihydroxyphenyl)ethanol (hydroxytyrosol, HTy) and hydroxy-
tyrosyl acetate (HTy-Ac), which have a wide range of anti-
inflammatory, anti-oxidant, and chemopreventive function in
vitro.[14–17] These beneficial properties were confirmed in vivo in
animal models of autoimmunity.[18–21]
The interest in dietary supplements and natural therapies
in the management of skin disorders is increasing. However,
despite favorable effects in inflammatory processes, the poten-
tial of EVOO or its derivatives in mitigating skin inflammation
has not been addressed so far.
Here, we report that HTy-Ac and HTy interfere with the
nuclear factor “kappa-light-chain-enhancer” of activated B-cells
(NF-𝜅B) pathway by reducing inhibitor of kB (I𝜅B) degradation,
NF-𝜅B nuclear translocation, NF-𝜅B promoter recruitment, and
NF-𝜅B-driven transcription. In doing so, EVOO polyphenols ef-
ficiently attenuate the expression of pro-inflammatory mediators
such as TSLP, thereby restraining harmful processes set off by
activated keratinocytes.
2. Experimental Section
2.1. Extraction and Chemical Characterization
HTy, obtained from olive mill wastewaters,[22] was used after
purification by column chromatography (ethyl acetate (EtOAc)-
cyclohexane 1:5→ 1:2). The synthesis of HTy-Ac was carried out
from HTy according to a published protocol.[20]
2.2. Keratinocyte Isolation and Treatments
Human keratinocytes were isolated from foreskins and
propagated according to a published protocol with several
modifications.[23] The skin was obtained from circumcisions,
with informed consent of the patients or their legal guardians
and approval by the Charité University ethics committee. The
experiments were conducted according to the Declaration of
Helsinki principles. Briefly, cells were pretreated with HTy or
HTy-Ac (12.5–100 µm) for 30 min and then stimulated with
recombinant human (rh) IL-1𝛽 (10 ng mL–1) (Immunotools,
Friesoythe, Germany) or Toll-like receptor 3 ligand (TR3-l)
(10 µg mL–1) (Poly I:C) (Invivo Gen, Toulouse, France) for
different experimental time points. The detailed method can be
found in the Supporting Information.
2.3. Cell Viability Assay
Cell viability was measured by the 2-(2-methoxy-4-nitrophenyl)-
3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, mono-
sodium salt (WST-8) cell viability kit (Cayman, Chemical Com-
pany, Ann Arbor, USA). The results are expressed in relation to
the percentage of untreated control cells. The detailed method
can be found in the Supporting Information.
2.4. ELISA
Cells (7.5 × 103cells) were used per well and treated as described
in Section 2.2. Supernatants were collected after 24 h and mea-
sured by TSLP ELISA (eBioscience, SanDiego, USA). Quantifica-
tionwas performed as per themanufacturer’s instruction and the
results were expressed in relation to the (IL-1𝛽 or TLR3-l) stimu-
lated control.
2.5. Quantitative Reverse-Transcriptase Polymerase
Chain Reaction
RNA was reverse transcribed with TaqMan reverse transcription
reagents (Applied Biosystems, Darmstadt, Germany) and quanti-
tative reverse-transcriptase PCR (RT-qPCR) was performed with
the Fast Start DNA Master SYBR Green I and LightCycler
1.5 (Roche Diagnostics, Mannheim, Germany) according to the
manufacturer’s protocol. Oligonucleotide primers (TIB Molbiol,
Berlin, Germany), product sizes, and temperatures are specified
in Table S1, Supporting Information. Expression levels of the tar-
get gene were quantified relative to the expression of the refer-
ence gene 𝛽-actin using the 2–ΔΔCT method. The relative expres-
sion values (i.e., TSLP normalized to 𝛽-actin for each cDNA in-
dividually) were expressed in relation to the stimulated control
cells (IL-1𝛽 or TR3-l).
2.6. Immunoblottting Detection
Cells (1.2 × 105 cells per well in six-well plates) were treated as de-
scribed in Section 2.2 and then stimulated for 5, 30, and 60 min.
Proteins were transferred to polyvinylidene fluoride (PVDF)
membranes (Amersham Biosciences, Freiburg, Germany),
blocked for 1 h with 10% casein and 5% sucrose/PBS, and
incubated overnight at 4 °C with the specific primary antibody at
1:1000 (rabbit anti-I𝜅B𝛼 or rabbit anti-p65; Cell Signaling, Dan-
vers, MA) in 10% casein and 5% sucrose/PBS. After washing the
membrane with PBS-Tween, HRP coupled secondary antibody
goat anti-rabbit (Dako, Glostrup, Denmark; 1:10 000) was added
for 2 h at room temperature. The immunosignals were captured
using Fusion FX7 Spectra (VilberLourmat, Eberhardzell, Ger-
many). The results were densitometrically analyzed by using
freeware Image J (National Institutes of Health, Bethesda,
MD). The detailed method can be found in the Supporting
Information.
2.7. Chromatin Immunoprecipitation (ChIP) Assay
Cells (1.2 × 105 cells per well in six-well plates) were treated
as described in Section 2.2 and then stimulated for 30 min.
Mol. Nutr. Food Res. 2019, 63, 1900019 1900019 (2 of 10) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.mnf-journal.com
After incubation chromatin was prepared using Chromatrap
Enzymatic Shearing Kit (Chromatrap, Wrexham, UK) following
manufacturer’s instructions and was checked on 1% agarose gel
for appropriate size of sheared chromatin. The chromatin was
further processed using Abcam high sensitivity ChIP Kit (Ab-
cam, Cambridge, UK) according to manufacturer’s instructions
and the immunoprecipitation was carried out using rabbit anti-
human-NF-𝜅B p65 antibody (Active Motif, La Hulpe, Belgium)
and normal rabbit IgG (Cell signaling, Beverly). After purifi-
cation, DNA was analyzed using Fast Start DNA Master SYBR
Green I and the Light Cycler 1.5 device (Roche Diagnostics,
Mannheim, Germany). ChIP DNA was normalized according to
the input DNA. The sequence of primers and PCR conditions
are given in Table S2, Supporting Information. The primers
for NF-𝜅B BS present in human IL-8 promoter were purchased
from Qiagen (Hilden, Germany) Epitect ChIP qPCR assay.
2.8. Luciferase Reporter Assay and Cell Transfection
Cells (1.2 × 105 cells per well) were transfected with human IL-8
promoter construct (pGL4.15-basic vector encoding human IL-8
promoter; Promega, Madison, USA) or empty vector. Transient
transfection of keratinocytes was performed using TransIT Ker-
atinocyte transfection reagent (Mirus Bio LLC, Madison, USA)
according to the manufacturer’s instructions. To assess the IL-
8 promoter luciferase activity, 1.5 µg of IL-8 promoter construct
and 0.5 µg of Renilla luciferase reporter vector pRL-TK (Promega)
were co-transfected in each well for 24 h. After 24 h, cells were
washed twice with PBS and were lysed using lysis buffer. The lu-
ciferase activity wasmeasured by the dual-luciferase assay system
kit according to the manufacturer’s protocol (Promega, Madison,
USA) using a VictorTMX3 luminometer (PerkinElmer,Waltham,
USA). All values were normalized to Renilla luciferase activity
and expressed relative to the control (transfected non-stimulated
cells).
2.9. Statistical Analysis
Values are expressed as arithmetic mean ± SEM. The data were
analyzed withGraphPad PrismVersion 5.01 software (SanDiego,
CA). Statistical significance was assessed by one-way analysis of
variance using repeated measures test and a nonparametric test
with Dunn’s test as post hoc test. p-Values of <0.05 were consi-
dered statistically significant.
3. Results
3.1. EVOO Polyphenols do not Compromise Keratinocyte
Survival
We first assessed the impact of HTy-Ac and HTy on keratinocyte
viability by WST-8 survival assay. Viability was not compromised
at concentrations from 0 to 100 µm of either HTy-Ac or HTy
(Figure S1, Supporting Information). However, a concentration
of 500 µm resulted in decreased viability. Based on this pattern,
we decided to assay the compounds at concentrations from 12.5
to 100 µm in subsequent experiments.
3.2. EVOO Polyphenols Counter TSLP Induction in Human
Keratinocytes
TSLP is associated with inflammatory processes of the skin and
disorders like atopic dermatitis.[4,6,24] To induce TSLP production,
keratinocytes were stimulated with IL-1𝛽 and TLR3-l based on
previous studies from our laboratory.[4] To determine the effect
of EVOO polyphenols, keratinocytes were pretreated for 30 min
with HTy-Ac or HTy and stimulated for 24 h. Stimulation with
IL-1𝛽 (Figure 1A) or TLR3-l (Figure S2, Supporting Information)
stimulated TSLP production. HTy-Ac or HTy prevented induc-
tion by IL-1𝛽 (Figure 1A). These effects were comparable when
TLR3 ligation was used as stimulus (Figure S2, Supporting In-
formation). A similar trend was noted for the low baseline TSLP
production, indicating that both compounds broadly decreased
TSLP production (data not shown).
We explored whether the attenuation of TSLP protein was
reflected at the transcript level. Indeed, while TSLP mRNA
expression was remarkably induced following IL-1𝛽 or TLR3-
l stimulation (Figure 1B; Figure S4, Supporting Information),
HTy-Ac or HTy effectively countered this transcriptional induc-
tion (Figure 1B; Figure S4, Supporting Information). In hu-
mans, two TSLP isoforms are produced: a short isoform that
mediates homeostatic functions and a long isoform weakly ex-
pressed at steady state and upregulated by tissue damage or
inflammation.[10] We studied expression of the two isoforms se-
parately. The long isoform was indeed increased to 100-fold over
control by IL-1𝛽 stimulation (Figure 1C). Treatment with HTy-Ac
or HTy significantly counteracted this induction (Figure 1C).
The expression of the short isoform was not significantly al-
tered by IL-1𝛽, and HTy-Ac and HTy did likewise not modulate
the short TSLP transcript (Figure 1D). We conclude that HTy-Ac
and HTy interfere with the induction of the long TSLP isoform.
3.3. EVOO Polyphenols Widely Modulate NF-𝜿B Target Genes,
But Have no Effect on Skin Structural Components
A major orchestrator of TSLP induction in inflammatory sur-
roundings is NF-𝜅B.[25–27] To assess whether EVOO phenols
broadly interfere with NF-𝜅B regulated genes in the skin, the ex-
pression of further candidates was quantitated by RT-qPCR. In-
deed, TNF-𝛼, IL-6, and IL-8 were induced by IL-1𝛽 or TLR3-l in
keratinocytes, and HTy or HTy-Ac were found to effectively inter-
fere with this induction (Figure 2; Figure S4, Supporting Infor-
mation).
Cyclooxygenase-2 (COX-2) is another downstream target of
NF-𝜅B and induced in skin inflammation.[28,29] Accordingly,
COX-2 expression was upregulated by IL-1𝛽 and HTy-Ac as well
as HTy counteracted this increase (Figure 2).
Our combined data implied that EVOOpolyphenols exert their
anti-inflammatory effects by interference with the NF-𝜅B path-
way in keratinocytes.
To assess whether inhibition was specific for inflammation-
related genes, we extended our analysis to genes encoding
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Figure 1. IL-1𝛽 induced TSLP production in human keratinocytes was inhibited by HTy and HTy-Ac. A) Levels of TLSP measured by ELISA in human
keratinocytes stimulated with IL-1𝛽 (10 ng mL–1) for 24 h. The data are given in percentage (%) of IL- 1𝛽 stimulated TSLP levels. Depending on the
experiment, IL-1𝛽 yielded concentrations of TSLP between 40 and 270 pg mL–1. B–D) Expression of TSLP (total), long and short TSLP isoforms by
RT-qPCR after 4 h of stimulation with IL-1𝛽 (10 ng mL–1), normalized to 𝛽 –actin. Keratinocytes were pretreated with the compounds for 30 min before
the addition of IL-1𝛽. DMSO served as vehicle control. Each column represents the mean ± SEM of at least five independent experiments. *p < 0.05;
**p < 0.01 versus IL-1𝛽 stimulated cells.
structural proteins of the skin, which are not believed to require
NF-𝜅B activity. Filaggrin and Loricrin play important roles in
the formation of the cornified layer of in the stratum corneum,
and their decreased expression is related to inflammatory skin
disease.[30] In our study, filaggrin and loricrin mRNA were not
significantly impacted by IL-1𝛽, and this was independent of the
presence of HTy-Ac or HTy (Figure S5, Supporting Information).
Collectively, while inflammatory mediators are potently reduced
by the polyphenols, genes important to an ordered architecture
of the skin remain unperturbed.
3.4. EVOO Polyphenols Restrain NF-𝜿B Activation in Human
Keratinocytes
To test our hypothesis that EVOO polyphenols suppress
inflammatory mediators by impairing NF-𝜅B activation in
keratinocytes, we explored their impact on I𝜅B𝛼 (the inhibitor of
NF-𝜅B) degradation byWestern blot. Beforehand, we established
that degradation of I𝜅B𝛼 was elicited by IL-1𝛽 in our setting
(Figure S3A, Supporting Information; degradation after 15 or 30
min of stimulation, followed by partial recovery at 60 min). The
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Figure 2. HTy and HTy-Ac counteracted the induction of NF-𝜅B dependent genes. Expression of TNF-𝛼, IL-6, COX-2, and IL-8 (normalized to 𝛽-actin)
by RT-qPCR. Cells were pretreated with HTy or HTy-Ac for 30 min and then stimulated with IL-1𝛽 for 4 h. Each column represents the mean ± SEM of at
least five independent experiments. *p < 0.05; **p < 0.01 versus IL-1𝛽 stimulated cells.
disappearance of I𝜅B𝛼 was associated with simultaneous translo-
cation of the NF-𝜅B member p65 to the nucleus (not shown, see
also Figure 3B). In the presence of HTy and HTy-Ac, both the
degradation of I𝜅B𝛼 and nuclear translocation ofNF-𝜅Bp65were
attenuated (Figure 3A,B; Figure S3B, Supporting Information).
Consequently, higher levels of I𝜅B𝛼 and lower nuclear levels of
p65 were detected at both time points analyzed. We conclude
that HTy and HTy-Ac counteract NF-𝜅B activation by restraining
I𝜅B𝛼 degradation and subsequent p65 nuclear translocation.
3.5. Recruitment of NF-𝜿B to Specific Promoters and NF-𝜿B
Transcriptional Activation are Curtailed by EVOO Polyphenols
Having established that the abundance of nuclear NF-𝜅B was
diminished by HTy or HTy-Ac treatment, we investigated the
binding of this factor to the endogenous TSLP promoter by
ChIP assay. As shown in Figure 4A, IL-1𝛽 de novo induced
its recruitment to the essential NF-𝜅B binding site located at
–3.8 kb upstream of the transcription start site (TSS).[12,25,26]
This interaction was markedly attenuated by HTy or HTy-Ac
(Figure 4A), corroborating the findings for p65 nuclear translo-
cation. To exclude nonspecific effects, an IgG isotype control was
used instead of the anti-NF-𝜅B antibody (Figure 4A). In addition,
recruitment of RNA polymerase to the 5’-upstream regions of
𝛽-actin and GAPDH served as control for the quality of our
ChIP technique. No binding of NF-𝜅B to the TSLP promoter
was detected in the absence of IL-1𝛽, while Pol II binding to the
regulatory regions of housekeeping receptors was unaffected
by IL-1𝛽 (data not depicted). As expected, specific binding of
RNA polymerase II to these promoter elements was comparable
across conditions, in accordance with the housekeeping-like
character of the genes (Figure 4B).
In addition to TSLP, many other cytokines and chemokines
are regulated by NF-𝜅B (compare also to Figure 2; Figure S4,).
We next selected the IL-8 promoter, a chemokine predominantly
regulated by NF-𝜅B to extend the analysis to another key in-
flammatory mediator and well-defined NF-𝜅B target.[31,32] As
expected, we found strong recruitment of NF-𝜅B to its binding
site at –0.86 kb of the IL-8 gene. Again, pretreatment with HTy
or HTy-Ac strongly inhibited this interaction (Figure 5A).
Furthermore, we used reporter assays to verify that reduced
NF-𝜅B binding had functional consequences to IL-8 promoter
activity. To this end, we first optimized the transfection method
for primary human keratinocytes. As shown in Figure 5B, the
stimulation with IL-1𝛽 indeed resulted in ≈17-fold induction of
reporter activity over baseline, validating the performance of our
method. Meanwhile, the pretreatment with EVOO polyphenols
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Figure 3. EVOO-compounds supressed I𝜅B𝛼 degradation and NF-𝜅B nuclear translocation. A) I𝜅B𝛼 degradation. B) p65 nuclear translocation. Cells
were untreated or treated with EVOO compounds (1 =HTy-Ac, 2 =HTy) for 30 min and then stimulated for 15, 30, and 60 min with IL-1𝛽. 𝛽-actin served
as loading control for normalization.
potently inhibited IL-8 promoter activation by IL-1𝛽 (Figure 5B),
in accordance with our ChIP findings. Therefore, we conclude
that the EVOOphenolic compoundsHTy andHTy-Ac inhibit NF-
𝜅B mediated transcription of inflammation-associated genes.
4. Discussion
We demonstrate herein that two phenolic compounds derived
from EVOO, namely HTy and HTy-Ac, attenuate inflamma-
tory responses of human keratinocytes and suppress key epider-
mal cytokines, including TSLP. Favorable properties have been
ascribed to EVOO in different contexts, and our study extends
them to the environment of human skin.
Since benefits from natural compounds can potentially be
achievedwithout the harmful or unwanted side effects of classical
pharmacological drugs, this appreciation has encouraged shifts
in biopharmaceutical research away from synthetic molecules
to natural products. In fact, natural products have already rev-
olutionized the management of several diseases in medical
practice.[33,34] Polyphenols, compounds with at least one aromatic
ring with a hydroxyl group attached to it, are active constituents
among plant-derived natural products and exhibit important in
vitro and in vivo properties, including anti-aging, antioxidant,
anti-inflammatory, anti-diabetes, anti-hypercholesterolemia, and
anticancer.[35–40]
EVOO polyphenols fit this picture, presenting qualities of
medical interest including anti-inflammatory and immune-
modulatory activities, only partially related to their antioxidant
power, which could be useful in the management of skin
diseases.[41–43] In this regard, a polyphenol-based cosmeceutical
containing olive polyphenol extract, exhibited positive skin
effects.[44] Along the same lines, an olive oil-based diet (10% of
total calories) improved cutaneous wound healing of pressure
injury in mice.[45] Besides, ex vivo topical administration of olive
oil (0.01 mg mL–1) was capable of attenuating the reduction
in epidermis and dermis thickness and collagen fiber content
induced by chronic stress in human skin.[46] The above reports
suggest that olive oil polyphenols are capable of tipping the
scales in the skin environment in vivo toward the maintenance
of homeostasis and anti-inflammation.
HTy is the best studied EVOO-derived polyphenol and a good
candidate for the development of drugs due to its prophylac-
tic and preventive effects in cells and animal models of can-
cer, lupus, and ischemia-reperfusion among others.[20,47–50] Even
though this is the first study to explore the impact of EVOO
polyphenols on inflammation-associated pathways in primary
keratinocytes of human origin, HTy was previously described
to exhibit chemoprotective and antiaging effects against ultra-
violet B (UVB) and blue-light-induced damage in human skin
cells.[51,52] In a mouse model of AD, HTy had beneficial effects,
reducing erythema intensity and dermatitis and decreasing T-
helper cell cytokines in serum and skin, albeit only in the pres-
ence of hydrocortisone.[53,54] Recently, a study evaluated the safety
of a cream with hydrocortisone and HTy, showing that long-term
use had a favorable safety profile, a finding encouraging further
clinical trials.[55]
HTy-Ac, found in EVOO at a proportion similar to HTy (de-
pending on the variety of olive), has been less studied, but re-
cently aroused interest among natural products. In this regard,
HTy-Ac moderated the inflammatory response in LPS-treated
macrophages by downregulating I𝜅B𝛼 degradation and COX-2
expression.[56] It showed beneficial effects in models of immune-
inflammatory disease, including systemic lupus erythematosus
and acute colitis.[20,48] Interestingly, HTy-Ac reduced inflamma-
torymarkers in amodel of murine arthritis, in whichHTy had no
effect, suggesting that (at least subtle) differences exist between
HTy and HTy-Ac as for their mode of operation.[21] However, the
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Figure 4. HTy and HTy-Ac prevented the recruitment of NF-𝜅B to the TSLP promoter. A) IL-1𝛽 mediated recruitment of NF-𝜅B at binding site located at –
3.8 kb of TSLP promoter. B) 𝛽-actin and GAPDH promoter regions served to verify that the binding intensity of RNA polymerase II to housekeeping genes
remained comparable across treatments. One representative experiment of three is shown. Cells were left untreated or treated with EVOO compounds
(1 = HTy-Ac, 2 = HTy) for 30 min and then stimulated for 30 min with IL-1𝛽.
effects specifically of HTy-Ac in the inflammatory process of the
skin remained unexplored.
In our study, the two polyphenols prevented inflammatory
responses in primary human keratinocytes with similar efficacy.
Both substances countered IL-1𝛽 and TLR3-l induced gener-
ation of TSLP protein, and this was mirrored at the level of
its transcript, where total TSLP mRNA and especially its long,
inflammation-associated isoform were diminished. In addition,
HTy and HTy-Ac dampened expression of diverse genes active in
an inflammatory environment (IL-8, TNF-𝛼, IL-6, and COX-2).
We succeeded in linking these effects to interference with NF-
𝜅B activation. NF-𝜅B is a central orchestrator of inflammation,
owing to its upstream and prominent position in the cascade
controlling expression of a myriad of pro-inflammatory genes.
Accordingly, NF-𝜅B hyper-activation is associated with chronic
diseases such as atherosclerosis, rheumatoid arthritis, and atopic
dermatitis and it is therefore believed to be a primary target of
anti-inflammatory therapeutics, including nutrients.[57]
In our study, we showed that HTy is able to modulate the NF-
𝜅B pathway, increasing the levels of nuclear p65 and decreasing
the cytosolic I𝜅B-𝛼 levels. IL-1 triggers a variety of concomitant
and sequential signaling events that encompass MyD88, several
IRAK members, TRAF6, MAP3K7, which then recruit and
activate IKK, p38, and JNK, respectively, resulting among other
in I𝜅B degradation and p65 nuclear translocation.[58] The single
events are interconnected by loops and feedback mechanisms,
causing a high degree of complexity in the IL-1 signaling net-
work. It will be of interest to delineate whether and which of the
above signaling intermediates are directly bound by the polyphe-
nols and thereby functionally modulated or attenuated.[58]
Another, not mutually exclusive possibility is through (a)
different signaling cascades, that feed(s) into the NF-𝜅B path-
way. Interesting candidates in this regard are 5′ AMP-activated
protein kinase (AMPK) and Sirtuin-1 (SIRT1), because previous
studies have demonstrated HTy to be a potent AMPK-SIRT1
activator in different in vitro models.[59–63]
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Figure 5. HTy and HTy-Ac interfered with IL-8 promoter activity. A) NF-𝜅B recruitment to the NF-𝜅B BS (at –0.86 kb) of the IL-8 promoter after IL-1𝛽
stimulation. pGL4.15-hIL-8 promoter (firefly)/pGL4.74 (renilla) and then normalized to control. One representative experiment of three is shown. B)
Induction of IL-8 promoter activity by IL-1𝛽. Each value represents the mean ± SEM of at least five independent experiments. Cells were treated with
EVOO compounds (1 = HTy-Ac, 2 = HTy) (or vehicle control) for 30 min and then stimulated for 24 h with IL-1𝛽. *p < 0.05; **p < 0.01 versus IL-1𝛽
stimulated cells.
Indeed, it has been reported that SIRT1 can be an inhibitor
of NF-𝜅B mediated transcription[64] and AMPK enhances SIRT1
activity,[65] and is likewise a modulator of the NF-𝜅B pathway on
its own.[65–67] However, there is so far only some first evidence of
this connection in keratinocytes. For example, Barroso et al[65] re-
ported that TNF-𝛼mediated activation of the NF-𝜅B pathway can
lead to TSLP mRNA expression in the HaCaT keratinocyte cell
line but that a peroxisome proliferator-activated receptor (PPAR-
𝛽/𝛿) agonist (GW501516) inhibited this process by activation of
PPAR𝛽/𝛿, AMPK, and SIRT1 pathways, respectively. While it is
not possible to extrapolate the described effects to our study due
to the different cells and models investigated by the previous
reports, it will be appealing to delineate the precise targets of
EVOOwithin the IL-1 and/or the AMPK cascades. EVOO pheno-
lic compounds might in fact act by a number of different effects
in keratinocytes, as it is well appreciated that different pathways
orchestrate the regulation of NF-𝜅B in a cell/stimulus specific
manner.
We need to emphasize, however, that EVOO polyphenols have
the power to potently interfere with NF-𝜅B in keratinocytes. We
were also able to kinetically resolve the mechanism of operation.
Both EVOO polyphenols acted by blocking I𝜅B𝛼 degradation and
thereby prevented p65 nuclear translocation, leading to reduced
presence of NF-𝜅B in the nucleus. The TSLP promoter contains
several NF-𝜅B binding sites (BS), of which the BS located at –3.8
kb is biologically active and responsive to stimulation by IL-1.[12,25]
While stimulation with IL-1𝛽 recruited NF-𝜅B to this site also in
our study, both HTy and HTy-Ac were able to efficiently inhibit
this recruitment, demonstrating that reduced nuclear presence
of NF-𝜅B had an effect at this promoter. To verify whether this
applies to other genes, as well, we selected the IL-8 promoter.
In agreement with previous studies, we found robust
recruitment of NF-𝜅B to the IL-8 promoter upon IL-1𝛽
stimulation.[31,68,69] This recruitment was potently blocked
upon pretreatment with both HTy and HTy-Ac. Interference at
the IL-8 promoter was even more pronounced than for TSLP,
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emphasizing that the consequences can differ across NF-𝜅B
binding sites even when NF-𝜅B reduction in the nucleus is
equal. We were finally interested to delineate whether the re-
duced binding of NF-𝜅B to the IL-8 promoter had functional
consequences to the transcriptional activity of this promoter. We
found that this was indeed the case. Using reporter constructs
in primary keratinocytes, we verified that IL-1-induced IL-8
promoter activity was potently inhibited by HTy or HTy-Ac,
complementing the attenuated binding of NF-𝜅B to the IL-8
promoter, as revealed by ChIP.
By demonstrating that EVOO phenols exert anti-inflammatory
effects on human keratinocytes, our study not only extends these
previous findings to also encompass HTy-Ac, but it shows that
human keratinocytes are direct targets of EVOO phenols, which
appears translationally interesting in the context of inflammatory
skin disorders, as also encouraged by the mentioned studies in-
vestigating the potential use of olive oil-derived compounds in
the field of dermatology.[35–46,51–55]
Taken together, we present evidence that EVOO polyphenols
counter inflammation initiated by human keratinocytes through
the attenuation of key inflammatory mediators commonly dereg-
ulated in the inflamed skin, including TSLP, and may provide
new avenues for the prophylaxis or treatment of inflammatory
dermatoses.
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